VNRX Rises on Landmark Co-Marketing Deal: Nu.Q® Discover Service Poised to Access $200 Million Market

Co-Marketing with Hologic Unlocks Expanded Reach for Nu.Q® Discover

In a significant development, VolitionRx Limited (NYSE: VNRX) has signed a co-marketing and services agreement with Hologic Diagenode to promote its Nu.Q® Discover service. This move immediately positions Volition's proprietary epigenetic profiling technology in front of Hologic’s extensive biotech and pharmaceutical client base, targeting a total addressable market of $200 million annually.

Under the agreement, Hologic (NASDAQ: HOLX), a global leader in medical technology with revenues exceeding $4 billion in 2024, will initially co-market Nu.Q® Discover services for one year. Success during this period could pave the way for Hologic to become the exclusive provider of these services—subject to further negotiation—substantially expanding Nu.Q® Discover’s reach and impact in pharmaco-epigenetics.

Nu.Q® Discover’s Platform Validated by Industry Heavyweight

Nu.Q® Discover offers drug developers and researchers state-of-the-art assays for rapid epigenetic profiling, ranging from early disease model development to market-ready clinical studies. The technology’s ability to quantify nucleosome-based biomarkers holds particular promise for advancing the understanding of disease progression and therapeutic response in cancer, cardiovascular, neurodegenerative, and immunological conditions.

Dr. Jasmine Kway, CEO of Volition’s Singapore division, emphasized, “This is a significant milestone for our Nu.Q® Discover program and will greatly expand customer access to our proprietary assays, which have an estimated total addressable market of $200 million annually.” Hologic’s established relationships and broad reach among global biotech and pharmaceutical firms create an immediate pipeline for Nu.Q® Discover, further validated by the inclusion in Hologic’s portfolio.

Industry Validation and Potential Revenue Acceleration

The partnership offers strong third-party validation for Volition’s technology. Hologic brings more than 20 years of experience in epigenomics and plans to market Nu.Q® Discover at conferences and webinars immediately, which could sharply accelerate adoption. Hologic’s Head of Life Sciences, Raphael Werding, noted the value of incorporating Nu.Q® Discover biomarkers to potentially unlock new biological insights, helping researchers match patients to the therapies most likely to benefit them—bolstering the promise of personalized medicine.

Volition’s Nu.Q® Discover technology leverages nucleosome quantification—a research area now gaining broader recognition as part of this collaboration. Early signs of increasing customer interest and revenue suggest that this expanded marketing effort could propel the platform’s visibility and sales growth, provided adoption and scientific results match the initial promise.

Market Position: Partnership with Hologic Could Accelerate Revenue Growth

With the co-marketing agreement in place and industry demand for advanced epigenetic assays on the rise, Volition is poised to expand its footprint rapidly. Success in this partnership could lead to Hologic becoming the exclusive distributor, solidifying Nu.Q® Discover’s position within a key segment of biotech research and pharmaceutical development.

Investors and stakeholders will want to monitor the agreement’s progress closely, as well as adoption metrics for Nu.Q® Discover over the coming quarters. A shift from a single-year pilot to a long-term exclusive deal could have outsized implications for both near-term revenue and the long-term market valuation of VolitionRx.

Takeaway: Watching for Exclusive Provider Status as Adoption Builds

This co-marketing agreement between VolitionRx and Hologic sets a new bar for industry collaboration in pharmaco-epigenetics. As the partnership unfolds, watch for key milestones: increased market adoption, revenue inflection points, and any announcement of Hologic’s move to exclusive provider status. These developments will be crucial indicators of VolitionRx’s traction in capturing a meaningful share of a fast-growing $200 million market opportunity.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI